Relmada Therapeutics, Inc. (RLMD) Advances Oncology and CNS Therapies with Promising Phase 2 Data [Yahoo! Finance]
Relmada Therapeutics, Inc. (RLMD)
NASDAQ:AMEX Investor Relations:
ir.relmada.com
Company Research
Source: Yahoo! Finance
Relmada Therapeutics, Inc. (NASDAQ:RLMD) is a clinical-stage biotech company that develops innovative therapies for oncology and central nervous system disorders. In 2025, the company will expand its pipeline with two Phase 2 candidates: NDV-01 for non-muscle invasive bladder cancer (NMIBC) and sepranolone for compulsivity disorders such as Prader-Willi Syndrome (PWS). In September 2025, Relmada Therapeutics, Inc. (NASDAQ:RLMD) reported promising Phase 2 results for NDV-01, a sustained-release formulation of gemcitabine and docetaxel, showing a 91% complete response rate. The firm is preparing to launch a Phase 3 registrational trial in early 2026. Sepranolone is also progressing toward a Phase 2 trial for PWS, with regulatory and manufacturing steps underway. Additionally, the business regained compliance with Nasdaq's minimum bid price requirement, ensuring continued listing and signaling market stability, placing it among the best penny stocks to watch in biotech. Relmada Ther
Show less
Read more
Impact Snapshot
Event Time:
RLMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLMD alerts
High impacting Relmada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLMD
News
- Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic OncologyGlobeNewswire
- Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Mizuho from a "neutral" rating to an "outperform" rating. They now have a $10.00 price target on the stock.MarketBeat
- Relmada Therapeutics GAAP EPS of -$0.30 [Seeking Alpha]Seeking Alpha
- Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025GlobeNewswire
- Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire
RLMD
Earnings
- 11/13/25 - Miss
RLMD
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/6/25 - Form 4
- 11/6/25 - Form 4
- RLMD's page on the SEC website